ALOMIDE
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALOMIDE is an ophthalmic solution approved by the FDA in 1993 for eye-related indications. It is a small-molecule drug administered as topical drops directly to the eye. The exact mechanism of action and indications are not specified in available data, but the product profile suggests use in allergic or inflammatory ocular conditions.
$0.064MPart D
LOE ApproachingProduct is in advanced stages of patent expiration with minimal commercial claims (241 in 2023), suggesting a small brand team focused on managed decline or niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ALOMIDE offers limited growth opportunities; the product is in managed decline with minimal Part D penetration and no linked job postings. Career progression would focus on defensive commercial strategies, market access, and generic transition planning rather than innovation or expansion.
Brand ManagerTerritory Manager / Field Sales
Worked on ALOMIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.